# A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

> **NCT05894083** · PHASE2 · RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 150 (estimated)

## Conditions studied

- Oropharyngeal Cancer
- Squamous Cell Carcinoma of the Oropharynx

## Interventions

- **PROCEDURE:** Surgery
- **COMBINATION_PRODUCT:** Chemoradiation
- **OTHER:** Observation
- **RADIATION:** Post-operative radiation

## Key facts

- **NCT ID:** NCT05894083
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-27
- **Primary completion:** 2026-12
- **Final completion:** 2030-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05894083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05894083, "A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05894083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*